Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $130.33.
Several brokerages recently weighed in on NKTR. Wedbush cut their price objective on shares of Nektar Therapeutics from $80.00 to $50.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 23rd. JPMorgan Chase & Co. assumed coverage on shares of Nektar Therapeutics in a research note on Friday, August 21st. They issued a “neutral” rating and a $65.00 price objective for the company. Raymond James Financial started coverage on shares of Nektar Therapeutics in a report on Friday, October 9th. They issued a “market perform” rating for the company. Leerink Partners initiated coverage on Nektar Therapeutics in a research report on Monday, October 12th. They issued an “outperform” rating and a $130.00 price target for the company. Finally, BTIG Research reissued a “buy” rating and issued a $178.00 price objective on shares of Nektar Therapeutics in a research note on Friday, October 9th.
Check Out Our Latest Research Report on Nektar Therapeutics
Nektar Therapeutics Stock Down 5.5%
Shares of NASDAQ NKTR opened at $32.54 on Friday. The firm’s 50-day simple moving average is $45.39 and its 200 day simple moving average is $64.50. The stock has a market cap of $1.11 billion, a P/E ratio of -5.04 and a beta of 1.44. Nektar Therapeutics has a fifty-two week low of $32.51 and a fifty-two week high of $109.00.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last released its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, topping analysts’ consensus estimates of ($2.07) by $0.44. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 29.31%. The business had revenue of $9.39 million for the quarter, compared to the consensus estimate of $10.27 million. On average, sell-side analysts anticipate that Nektar Therapeutics will post -7.39 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Nektar Therapeutics
A number of hedge funds have recently bought and sold shares of the company. Two Seas Capital LP boosted its stake in Nektar Therapeutics by 8.2% during the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock valued at $202,582,000 after purchasing an additional 253,744 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Nektar Therapeutics by 171.9% in the third quarter. Goldman Sachs Group Inc. now owns 621,249 shares of the biopharmaceutical company’s stock valued at $37,614,000 after acquiring an additional 392,759 shares during the period. Braidwell LP boosted its position in shares of Nektar Therapeutics by 112.7% in the second quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock valued at $33,063,000 after acquiring an additional 250,916 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Nektar Therapeutics in the first quarter worth $19,786,000. Finally, ADAR1 Capital Management LLC grew its stake in shares of Nektar Therapeutics by 123.9% in the first quarter. ADAR1 Capital Management LLC now owns 161,252 shares of the biopharmaceutical company’s stock worth $11,602,000 after acquiring an additional 89,221 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors.
Top Nektar Therapeutics Stories
These are some of the NKTR stories that stood out recently:
- Positive Sentiment: HC Wainwright raised its EPS estimates across several periods, including FY2026 and FY2027, while maintaining a Buy rating and $185 price target. Its revisions imply smaller projected losses in the near term and higher FY2030 EPS of $0.59, which could support investor optimism. Nektar Therapeutics analyst coverage
- Neutral Sentiment: CEO Howard Robin and insider Jonathan Zalevsky sold 429 and 192 shares, respectively. Both transactions were disclosed as covering tax withholding on vested equity awards, and each represented less than 3% of the seller’s holdings, making them less concerning than discretionary insider sales. CEO transaction filing
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Further Reading
- Five stocks we like better than Nektar Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
